title: Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.
abstract: Huntington's disease (HD) is an autosomal dominantly inherited progressive neurodegenerative disease. The exact sequel of events finally resulting in neurodegeneration is only partially understood and there is no established protective treatment so far. Some lines of evidence speak for the contribution of oxidative stress to neuronal tissue damage. The fumaric acid ester dimethylfumarate (DMF) is a new disease modifying therapy currently in phase III studies for relapsing-remitting multiple sclerosis. DMF potentially exerts neuroprotective effects via induction of the transcription factor "nuclear factor E2-related factor 2" (Nrf2) and detoxification pathways. Thus, we investigated here the therapeutic efficacy of DMF in R6/2 and YAC128 HD transgenic mice which mimic many aspects of HD and are characterized by an enhanced generation of free radicals in neurons. Treatment with DMF significantly prevented weight loss in R6/2 mice between postnatal days 80-90. At the same time, DMF treatment led to an attenuated motor impairment as measured by the clasping score. Average survival in the DMF group was 100.5 days vs. 94.0 days in the placebo group. In the histological analysis on day 80, DMF treatment resulted in a significant preservation of morphologically intact neurons in the striatum as well as in the motor cortex. DMF treatment resulted in an increased Nrf2 immunoreactivity in neuronal subpopulations, but not in astrocytes. These beneficial effects were corroborated in YAC128 mice which, after one year of DMF treatment, also displayed reduced dyskinesia as well as a preservation of neurons. In conclusion, DMF may exert beneficial effects in mouse models of HD. Given its excellent side effect profile, further studies with DMF as new therapeutic approach in HD and other neurodegenerative diseases are warranted.
authors.affiliation: Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
authors.forename: Gisa
authors.initials: G
authors.lastname: Ellrichmann
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Petrasch-Parwez
authors.forename: De-Hyung
authors.initials: DH
authors.lastname: Lee
authors.forename: Christiane
authors.initials: C
authors.lastname: Reick
authors.forename: Larissa
authors.initials: L
authors.lastname: Arning
authors.forename: Carsten
authors.initials: C
authors.lastname: Saft
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
authors.forename: Ralf A
authors.initials: RA
authors.lastname: Linker
mesh_terms: D000818:Animals; D000069462:Dimethyl Fumarate; D004195:Disease Models, Animal; D005650:Fumarates / Q000627:therapeutic use*; D006816:Huntington Disease / Q000188:drug therapy*; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D005650:Fumarates; D018696:Neuroprotective Agents; D000069462:Dimethyl Fumarate